A central role for the mammalian target of rapamycin (mTOR) in innate immunity has been recently defined by its ability to limit proinflammatory mediators. While glucocorticoids (GC) exert potent anti-inflammatory effects in innate immune cells, it is currently unknown whether the mTOR pathway interferes with GC signaling. Here we show that inhibition of mTOR with rapamycin or Torin1 prevented the antiinflammatory potency of GC both in human monocytes and myeloid dendritic cells.
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Abstract
A central role for the mammalian target of rapamycin (mTOR) in innate immunity has been recently defined by its ability to limit proinflammatory mediators. While glucocorticoids (GC) exert potent anti-inflammatory effects in innate immune cells, it is currently unknown whether the mTOR pathway interferes with GC signaling. Here we show that inhibition of mTOR with rapamycin or Torin1 prevented the antiinflammatory potency of GC both in human monocytes and myeloid dendritic cells.
GC could not suppress NF-κB and JNK activation, the expression of proinflammatory cytokines, and the promotion of Th1 responses when mTOR was inhibited.
Interestingly, long-term activation of monocytes with LPS enhanced the expression of TSC2, the principle negative regulator of mTOR, while dexamethasone blocked TSC2 expression and reestablished mTOR activation. Renal transplant patients receiving rapamycin but not those receiving calcineurin inhibitors displayed a state of innate immune cell hyperresponsiveness despite the concurrent use of GC. Finally, mTOR inhibition was able to override the healing phenotype of dexamethasone in a murine LPS shock model. Collectively, these data identify a novel link between the glucocorticoid receptor and mTOR in innate immune cells, which is of considerable clinical importance in a variety of disorders including allogeneic transplantation, autoimmune diseases, and cancer.
Introduction
Current immunosuppressive regimens to avoid allogeneic rejection after organ or bone marrow transplantation largely rely on drugs with potent immunosuppressive effects predominantly affecting different steps during T-cell activation. There is, however, increasing evidence that also the innate immune system is critical for the fate of allografts and may as well exert detrimental effector functions. [1] [2] [3] [4] [5] [6] [7] [8] [9] For example, monocytes are the first cells to enter the allograft immediately after transplantation and recently monocyte-rather than T-cell-influx into the allograft has been proposed to correlate with graft rejection. 9 Monocytes, macrophages, and dendritic cells (DCs)
initiate the inflammatory response after stimulation by Toll-like receptor (TLR) ligands and trigger the subsequent adaptive T-cell response. 10, 11 However, the molecular pathways targeted by immunosuppressants in particular when they are employed as combination therapy and the ensuing functional consequences are still incompletely defined.
Among the currently employed immunosuppressants calcineurin inhibitors (CNI) like cyclosporine A (CsA) or FK506 and antimetabolites like mycophenolic acid (mycophenolate mofetil, MMF) are thought to exert distinct but rather modest effects on innate immune cells. 12, 13 On the contrary, glucocorticoids (GC) have a high antiinflammatory potential and, consequently, are crucial constituents of various immunosuppressive regimens applied in many inflammatory conditions. 14 GC differentially affect cytokine production in monocytes/macrophages with a prominent shift towards an anti-inflammatory phenotype. 15 Furthermore, DC differentiation and maturation is profoundly suppressed by GC leading to DCs with a tolerizing capacity characterized by increased interleukin (IL)-10, but blocked IL-12 secretion. 16, 17 At the molecular level GC profoundly inhibit nuclear factor-κB (NF-κB) signaling via the For personal use only. on . by guest www.bloodjournal.org From glucocorticoid receptor (GR) to prevent recruitment of active NF-κB dimers to the κB promoter. 18 Moreover, it has been demonstrated that the c-Jun N-terminal kinase (JNK) pathway that specifically leads to the activation of the transcription factor subunit c-Jun is blocked by transrepression through nuclear GR binding. 19 Thus, NF-κB and JNK are major targets of GC to exert their anti-inflammatory action.
Interestingly, NF-κB and JNK are important for the allogeneic immune response as their hyperactivation may ultimately lead to allograft rejection in diverse experimental models.
20-24
The mammalian target of rapamycin (mTOR) pathway, which is known to control metabolism, growth, and cell survival, has recently emerged as key regulator of innate immune cell homeostasis. 25, 26 Inhibition of mTOR by rapamycin in human monocytes or myeloid dendritic cells promotes IL-12, IL-23, TNF-α, and IL-6 production via the transcription factor NF-κB but blocks the release of IL-10 via
Stat3
. [27] [28] [29] [30] Conversely, deletion of TSC2, the key negative regulator of mTOR, diminishes NF-κB but enhances Stat3 activity and reverses the proinflammatory cytokine shift. 27 Rapamycin can augment inflammation and pulmonary injury by enhancing NF-κB activity in the lung of tobacco-exposed mice. 31 
Methods
Cell isolation and culture
Peripheral blood mononuclear cells (PBMCs) were prepared from buffy coats by density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare). Peripheral blood CD14+ monocytes were isolated from PBMCs by positive selection using CD14 (Miltenyi) microbeads and a magnetic cell seperator. Myeloid DCs were isolated as described.
26 THP-1, a promonocytic cell line derived from human acute lymphocytic leukaemia patient was obtained from the DSMZ. Tsc2+/+ p53-/-and Tsc2-/-p53-/-mouse embryonic fibroblasts (MEF) were a kind gift of David
Kwiatkowski. Cells were cultured in RPMI 1640 (Invitrogen) containing penicillin (100 U/ml), streptomycin (100 μ g/ml), glutamine (2 mM) and 10% fetal calf serum (FCS) that had been inactivated at 56°C for 30 min. MEFs were cultured in DMEM containing 4.5 g/L glucose, 2 mM L-glutamine, 100 µg/ml streptomycin, 100 U/ml penicillin, and 10% FCS.
Reagents
Lipopolysaccharide from Escherichia coli 0111:B4 (LPS) was purchased from Sigma.
Dexamethasone (Dex), MMF, CsA and FK506 were purchased from Calbiochem.
Rapamycin was used from Calbiochem or was provided by Wyeth Pharmaceuticals with identical results. Torin1 was a kind gift of Nathanael Gray. 37°C at 5% CO 2 and 95% humidity before 100 nM rapamycin was added. Cells were left untreated or stimulated with LPS (100 ng/ml) for 24h. Cell-free supernatants were harvested, stored at -20°C and thawed at the time of analysis for IL-12p40, IL-10 and TNF-α production via Luminex.
Cell stimulation and collection of supernatants
Whole-blood stimulation
Heparinized blood from immunosuppressed renal transplant patients was diluted 1:5 in medium. 1 ml was added into 24-well plates and directly stimulated with 1 μg/ml LPS for 20 h. Cytokines were determined in cell-free supernatants by Luminex. 
Luminex
Cytokines were measured by Luminex technology to IL-12p40, IL-10, IL-6, TNF-α, and MCP-1 (all R&D Systems), and IL-23 (Bender MedSystems).
RNAi
THP-1 cells were transfected in full medium without antibiotics with 100nM ONTARGETplus SMARTpool human TSC2 or 100nM ON-TARGETplus siCONTROL non-targeting pool (Dharmacon) using Lipofectamine RNAiMAX (Invitrogen) following the protocol provided by the manufacturers. Cells were used after 72 h. 
Analysis of signal transduction events
Cell Fractionation
Nuclear and cytoplasmic fractions were obtained by discontinuous density gradient centrifugation. Briefly, cells were applied onto a preformed iodixanol gradient and centrifuged in the cold at 1000g for 15 min. Subsequently the different layers containing either cytosolic proteins or intact nuclei were harvested and solubilized in Laemmli-Buffer containing 150mM DTT by incubation at 95°C for 5 minutes.
T-cell proliferation
T lymphocytes were cultured at 1x10 6 
T-cell differentiation
Monocytes were incubated with medium, 100 nM rapamycin and/or 25 nM dexamethasone for 90 minutes and then stimulated with 100 ng/ml LPS for 24 h.
Then the cells were washed and incubated with allogeneic PBMCs at a ratio of 1:1 for one week. Afterwards IFN-γ was determined in the supernatants by ELISA. In parallel the cells were primed with 50 ng/ml PMA and 200 ng/ml ionomycin for 5 h in 
Quantitative RT-PCR
2x10
6 monocytes in a 6-well plate pretreated with or without dexamethasone and rapamycin as indicated were stimulated for 8 h with 100 ng/ml LPS and total RNA was extracted in TRIzol (Invitrogen). cDNA was generated by Superscript II (Invitrogen) as suggested by the manufacturer. mRNA levels were determined by TaqMan Gene Expression Assays for IL-12p40, IL-10, and 18S rRNA (Applied Biosystems) on a ABI Prism 7000 in a multiplex PCR. mRNA levels were normalized to 18S rRNA.
Reporter Gene Assays
The reporter construct for NF-κB was from Stratagene. p65(TAD) and Gal4-Luc 
Results
Hyperactivation of the inflammatory immune response in rapamycin-treated kidney transplant recipients
Our previous results indicated that rapamycin hyperactivates the inflammatory immune response in vitro in men and in vivo in mice. 26, 27 We confirmed in human monocytes that rapamycin strongly enhanced the production of IL-12p40, IL-12p70, and TNF-α, whereas production of IL-10 was blocked ( Figure 1A ). To substantiate these results ex vivo, we analyzed the production of inflammatory cytokines in whole blood from stable renal transplant recipients treated with rapamycin, CsA, or FK506
along with MMF and prednisolone. Apart from the steroid dose of FK506 patients, the patients characteristics were similar between the groups (Table 1) . Remarkably, patients on rapamycin were exceptionally susceptible to mount a profound proinflammatory response after ex vivo LPS stimulation reflected by a significantly higher production of the inflammatory markers IL-12p40, IL-6, TNF-α, and IL-1β
( Figure 1B) . Moreover, the anti-inflammatory cytokine IL-10 was significantly suppressed in these patients compared to FK506-patients ( Figure 1B) . Ex vivo addition of rapamycin monocytes from CsA-or FK506-patients similarly augmented IL-12p40 and suppressed of IL-10 expression (data not shown). Interestingly, IL12p40 production significantly correlated with the dose of prednisone only in CsAand FK506-patients but not in rapamycin-treated patients ( Figure 1C ). These results establish that rapamycin-treated kidney transplant patients display a profound proinflammatory profile upon TLR activation compared to CNI-treated patients.
Interference of rapamycin and other immunosuppressants in PBMCs
For personal use only. on . by guest www.bloodjournal.org From As therapeutic principle, mTOR inhibition is clinically applied with other immunosuppressive and anti-inflammatory drugs to enable an efficient immunosuppression. As we observed a powerful capability of rapamycin-treated patients to mount a proinflammatory response in the presence of MMF or GC, we investigated if these immunosuppressants are able to interfere with the immunomodulatory capacity of rapamycin at the cellular level. However, testing the immunosuppressive potency of GC and rapamycin after TCR activation, we observed that treatment with dexamethasone and rapamycin synergistically suppressed IFN-γ and IL-2 secretion after OKT-3 stimulation ( Figure   2D ) and both drugs also synergistically inhibited T-cell proliferation ( Figure 2E 
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These results demonstrate that rapamycin specifically prevents the anti-inflammatory effects of GC in PBMCs, but both drugs act in a synergistic immunosuppressive manner.
mTOR inhibition prevents the anti-inflammatory effect of dexamethasone in human monocytes
To specifically allocate the observed reciprocal influence of rapamycin and dexamethasone on inflammatory cytokines to a distinct cell type in PBMCs, we assessed purified human monocytes, the cardinal inflammatory cells in human blood.
Dexamethasone and rapamycin did not significantly affect apoptosis rates in LPS- indicating that rapamycin and dexamethasone might modulate similar downstream signaling pathways, whereas MMF and CNI did not significantly modulate cytokine production (data not shown). Moreover, rapamycin potently inhibited IL-10, and also the anti-inflammatory chemokine MCP-1, which could not be rescued by addition of dexamethasone ( Figure 3D-E) . As DCs are the major antigen-presenting cells that link innate with adaptive immunity, we wanted to assess whether inhibition of mTOR is able to overcome the anti-inflammatory effects of GC also in this cell compartment.
Employing freshly isolated myeloid DCs we found a similar conspicuous regulation of IL-12p40 production by rapamycin and dexamethasone ( Figure 3F ). These results suggest that the antagonism of mTOR and GR at the cellular level occurs both in monocytes and peripheral myeloid DCs. 
mTOR and the GR differentially regulate the activation of NF-κB in monocytes
To further address the molecular targets responsible for the observed reciprocal regulation of the proinflammatory response, we employed pharmacologically distinct agents to modulate the mTOR pathway and the GR. Indeed, the mTOR inhibitor Torin-1 was able to enhance IL-12p40 production despite the presence of dexamethasone ( Figure 4A ) and moreover, blocked IL-10 production in human monocytes ( Figure 4B ). On the other hand, treatment of monocytes with hydrocortisone similar to dexamethasone did not prevent rapamycin-induced hyperproduction of IL-12p40 ( Figure 4C ), while IL-10 was not modulated by hydrocortisone ( Figure 4D ). Together these results indicate that the proteins mTOR and the GR directly mediate the reciprocal effects of the inhibitors on inflammatory cytokine production. , while dexamethasone has potent inhibitory effects on NF-κB activity.
41,42 Therefore, we examined whether mTOR and the GR might reciprocally interact with NF-κB. While dexamethasone completely suppressed NF-κB activation in LPS-stimulated monocytic THP-1 cells, dexamethasone could no longer repress this transcription factor in the presence of rapamycin ( Figure 5C ). Only at a supramaximal dose, dexamethasone blocked NF-κB activation when mTOR was inhibited ( Figure 5C ). Next, we analyzed rapamycin-and dexamethasone-dependent NF-κB activation in Tsc2-/-murine embryonic fibroblasts, which display augmented mTOR signaling and are therefore refractory to LPS-induced NF-κB activation 27 ( Figure 5D ). While dexamethasone decreased NF-κB in LPS-stimulated cells, dexamethasone did not block rapamycin-induced NF-κB hyperactivation suggesting that the anti-inflammatory action of the GR involves the activation of mTOR signaling ( Figure 5D ). The transactivation domain (TAD) of p65 recruits specific cofactors to enhance the transcriptional process. 43 Interestingly, p65(TAD) was hyperactivated when mTOR was inhibited in LPS-stimulated THP-1 cells, while dexamethasone could not decrease this activity either alone or in the presence of rapamycin suggesting that the TAD of p65 is not reciprocally regulated by mTOR and the GR Figure 5E ). Collectively, these results demonstrate that the potent inhibitory effects of dexamethasone on the major proinflammatory transcription factor NF-κB are abrogated by rapamycin in monocytes indicating that a major part of the reciprocal regulation of proinflammatory cytokines by mTOR and the GR are mediated at the level of NF-κB signaling.
Rapamycin mediates proinflammatory effects via the GR-sensitive JNK signaling pathway
To further dissect molecular mechanisms apart from NF-κB that might be modulated by mTOR and the GR, we investigated if dexamethasone is able to directly interfere with mTOR signaling. Dexamethasone did not considerably affect the phosphorylation status of S6 or 4E-BP1, two downstream mediators of mTOR, in monocytes or THP-1 cells after 30 min of LPS stimulation ( Figure 6A-B) . In contrast dexamethasone blocked the phosphorylation of c-Jun ( Figure 6B ), an essential transcription factor subunit important for IL-12p40 production, while the mitogenactivated protein kinases Erk-1/2 and p38 were not modulated either by rapamycin or dexamethasone ( Figure 6A-B) . Recent data demonstrated a selective enhancement of JNK activity in mTOR-inhibited monocytes independent of c-Jun phosphorylation.
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Consistent with these results, SP600125, a specific inhibitor of JNK, completely abolished the enhanced production of IL-12p40, IL-23, and TNF-α by rapamycin ( Figure 6C ). To identify the underlying molecular mechanism explaining how increased JNK activity upon mTOR blockade may lead to enhanced transcriptional activity, we directly assessed the nuclear levels of c-Jun. Rapamycin increased the nuclear levels of c-Jun, while dexamethasone prevented the effects of mTOR inhibition ( Figure 6D ). Hence, one molecular mechanism contributing to the proinflammatory action of rapamycin is the selective enhancement of JNK activity
leading to increased nuclear c-Jun levels upon TLR engagement. However, the additional usage of dexamethasone to rapamycin-and SP600125-treated cells further downregulated IL-12p40 production after 24 h to a level comparable to dexamethasone-treated cells only (Fig. 6E) indicating that dexamethasone may exert additional effects to affect IL-12p40 expression. Therefore, we analyzed whether long-term treatment with dexamethasone might modulate the mTOR pathway.
Strikingly, we observed that LPS stimulation of THP-1 cells for 24 h upregulated TSC2 protein levels ( Figure 6F ). Dexamethasone completely blocked the LPSinduced increase of TSC2 levels and led to a concurrent activation of the mTOR pathway as shown by phosphorylation of S6 ( Figure 6F ). Activation of S6 negatively depended on TSC2 as knockdown of TSC2 increased S6 phosphorylation under all conditions tested ( Figure 6F ). These results were also observed in LPS-stimulated monocytes, where long-term treatment with dexamethasone increased S6 activity as well, whereas rapamycin abrogated the positive input signal from the GR to the mTOR pathway ( Figure 6G ). These results reveal a novel link between the GR and the mTOR pathway at the level of TSC2 and suggest that long-term treatment with dexamethasone may activate the mTOR signaling to regulate the inflammatory response.
Rapamycin overrides the beneficial effects of dexamethasone in a murine sepsis model
After having established that mTOR and the GR reciprocally regulate inflammatory cytokine production in innate immune cells in vitro and ex vivo, we wondered whether the anti-inflammatory potency of GC can be overcome by rapamycin in a murine LPS shock model. Recently, it has been shown that rapamycin augments lethality and proinflammatory cytokine production in LPS-treated C57BL/6 mice. 30 Similarly, we also observed that rapamycin significantly increased mortality, when mice were injected with an LD 30 LPS dose ( Figure 7A ), while in contrast, dexamethasone completely prevented mortality ( Figure 7A ). Remarkably, dexamethasone was not able to rescue rapamycin-treated animals from death ( Figure 7A ) suggesting that rapamycin overrides the beneficial effects of GC also in a relevant inflammatory disease model in vivo. While rapamycin inhibited IL-10 production in septic mice in vivo, dexamethasone did not reestablish IL-10 expression in mTOR-inhibited animals ( Figure 7B ). In addition, while dexamethasone completely repressed IL-12p70 production, rapamycin still allowed expression of bioactive IL-12p70 when the GR was activated in septic mice ( Figure 7B ). These results show that rapamycin enhances lethality in an LPS-shock model in vivo despite concurrent treatment with an effective anti-inflammatory intervention.
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Discussion
The molecular mode of action of medically approved drugs in transplantation medicine is still surprisingly ill-defined in particular when used in combination but is mandatory for the assessment of drug-related risks and also novel therapeutic avenues. Hence, the elucidation of the effects of currently employed immunosuppressive agents and regimens on the innate immune system is crucial as the evidence of the importance of monocytes and DCs for allograft rejection and survival is progressively increasing. Our studies reveal an unexpected and novel link between the GR and the mTOR pathway. Inhibition of mTOR enhances the production of IL-12, whereas it negatively regulates IL-10 in human monocytes and A connection between the mTOR pathway and the GR has been established in many cell lines. In these cells activation of the GR by GC induces the expression of RTP801 (also known as REDD1), which inhibits mTOR signaling. Clinically, it has been observed that distinct inflammatory side-effects of mTOR inhibitors including pneumonitis and glomerulonephritis cannot be ameliorated with GC. For instance, mTOR inhibitor-induced pneumonitis requires the discontinuation of the mTOR inhibitor despite the concurrent use of GC.
35,36
Moreover, myeloid DCs have a proinflammatory phenotype in rapamycin-treated patients despite concurrent prednisone therapy. 26 Our current results that clinically applicable doses of GC cannot ameliorate the inflammatory events observed with mTOR inhibitor therapy may provide one molecular rationale for this unusual phenomenon. Moreover, they support the notion that discontinuation of the mTOR inhibitor in such events might be favorable rather than escalating the steroid.
In conclusion, we could show in this study that the GR is connected with the mTOR pathway in human monocytes to modulate inflammatory responses. The potent anti-inflammatory effects of dexamethasone were rendered ineffective in the presence of rapamycin resulting in sustained production of proinflammatory cytokines. These data not only reveal a novel basic regulatory principle in innate immune cells, but also may allow to better understand the interaction of currently employed immunosuppressants within the innate immune cell compartment and finally may allow optimizing immunosuppressive protocols. 
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